AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.
We believe that OMIC technologies represent an important first step towards gaining biological insights into:
AROMICS invited to the Scientific Meeting of the European Academy of Nursing Sciences
Dr. Carmen Plasencia, CEO of AROMICS, was one of the invited speakers of the scientific meeting of...
http://www.youtube.com/user/AROMICSBiotech
AROMICS will participate at the meeting of PathoGenoMics
The european project CELLPATH where AROMICS participates, will be presented during the Anual Meeting...
With 35,000 genes and hundreds of thousands of protein states to identify, correlate, and characterize, the studies of one gene, gene product, or process are no longer reliable or cost-effective. We have entered the "omic" era in biology. But large- scale omic studies of cellular molecules in aggregate rarely answer interesting questions without the assistance of information from traditional hypothesis- driven research. These scientific methods are complementary and synergistic.
John N. Weinstein. Disease Markers 17(2): 77- 88, 2001.
